Granulocyte&#8211;colony stimulating factor plus plerixafor inpatients with &#8211;thalassemia major results in the effective mobilization of primitiveCD34+ cells with specific gene expression profile by Elena, B. et al.
                                        [Thalassemia Reports 2017; 7:6392]                                                         [page 11]
Granulocyte–colony stimulat-ing factor plus plerixafor inpatients with β-thalassemiamajor results in the effectivemobilization of primitiveCD34+ cells with specific geneexpression profile
Elena Baiamonte,1 Rita Barone,1
Flavia Contino,2 Rosalia Di Stefano,1
Anna Marfia,3 Aldo Filosa,4
Emanuela D’Angelo,5 Salvatore Feo,2
Santina Acuto,1 Aurelio Maggio1
1Campus of Hematology F. and P.
Cutino, Villa Sofia-Cervello Hospital,
Palermo; 2Department of Biological,
Chemical and Pharmaceutical Sciences
and Technologies and ATeN Center,
University of Palermo; 3Division of
Hematology, Villa Sofia-Cervello
Hospital, Palermo; 4Center for Anemias,
A. Cardarelli Hospital, Napoli;
5Pediatric Clinic De Marchi, Policlinico
Hospital, Milan, Italy
Abstract
Successful gene therapy for β-tha-
lassemia requires optimal numbers of autol-
ogous gene-transduced hematopoietic stem
and progenitor cells (HSPCs) with high
repopulating capacity. Previous studies sug-
gested superior mobilization in these patients
by the combination of granulocyte–colony
stimulating factor (G-CSF) plus plerixafor
over single agents. We mobilized four adult
patients using G-CSF+plerixafor to assess
the intra-individual variation of the circulat-
ing CD34+ cells number and subtypes pre-
and post-plerixafor administration. The pro-
cedure was well-tolerated and the target cell
dose of ≥8×106 CD34+ cells/kg was
achieved in three of them with one apheresis
procedure. The addition of plerixafor unani-
mously increased the number of circulating
CD34+ cells, and the frequency of the most
primitive CD34+ subtypes: CD34+/38- and
CD34+/133+/38- as well as the in vitro
clonogenic potency. Microarray analyses of
CD34+ cells purified from the leukapheresis
of one patient mobilized twice, with G-CSF
and with G-CSF+plerixafor, highlighted in
G-CSF+plerixafor-mobilized CD34+ cells,
higher levels of expression genes involved in
HSPC motility, homing, and cell cycles. In
conclusion, G-CSF+plerixafor in β-tha-
lassemia patients mobilizes optimal numbers
of HSPCs with characteristics that suggest
high capacity of engraftment after transplan-
tation.
Introduction
Autologous hematopoietic genetically
modified stem and progenitor cells
(HSPCs) represent an emerging therapeutic
option for curing β-thalassemia, particularly
in patients who lack a suitable donor for
allogeneic bone marrow transplantation
(BMT). In recent years, clinical trials of
gene therapy for β-thalassemia are ongoing
in multiple centers and proof-of-principle of
efficacy and safety has already been
obtained in a number of patients.1
The success of gene therapy for β-tha-
lassemia, in which engrafted gene-corrected
stem cells do not have a selective advantage
over unmodified cells, greatly depends on
the number and the quality of autologous
HSPCs collected for genetic modification.
Blood mobilization using granulocyte-
colony-stimulating factor (G-CSF) and col-
lection of HSPCs by apheresis, are relative-
ly easier and lesser invasive procedures
than BM withdrawal and yield high num-
bers of CD34+ cells. For these reasons
HSPCs mobilization represents a preferred
source for allogeneic and autologous BMT
in malignancies2 and, more recently, in stem
cell gene therapies.1,3-6
It has been reported that patients with
inherited hematological disorders respond-
ed differently to G-CSF stimulus. Indeed,
significantly impaired HSPC-mobilization
has been reported in patients with primary
immunodeficiency disorders.7,8 In addition,
in patients with sickle cell disease, the use
of G-CSF has been shown to precipitate
severe sickle cell crises and, in one case,
death.9,10 In patients with β-thalassemia, G-
CSF-induced hyper-leukocytosis and spleen
enlargement were found to be the major
dose-limiting factors ultimately resulting in
poor CD34+ cell yields.11-14
Plerixafor, is a recently available mobi-
lizing agent that promote HSC trafficking
by a mechanism different than G-CSF.
Plerixafor is an CXCR4 antagonist that
mobilizes HSCs within a few hours by dis-
rupting the engagement of the CXCR4 stem
cell receptor with its ligand (SDF-1), which
is expressed on marrow osteoblasts. In con-
trast, G-CSF indirectly mobilizes stem cells
by down-regulating the expression of SDF-
1 and by releasing proteolytic enzymes,
which degrades important HSC trafficking
and adhesion molecules.
Plerixafor promotes a more robust
mobilization when used in combination
with G-CSF in both healthy volunteers and
patients with hematologic diseases.15,16
Plerixafor, alone or in combination with
G-CSF, has also been used to improve the
yield of HSPCs in β-thalassemia patients.
Plerixafor, when used as single agent, was
safer than G-CSF. However, a third of
patients failed to achieve the pre-deter-
mined cell dose. Conversely, a combination
including G-CSF and plerixafor was shown
to be synergistic and to induce successfully
mobilization in four patients in whom sin-
gle agent-mobilization had previously
failed.14,17
Here, we report a clinical study of
mobilization via the use of G-
CSF+Plerixafor in four adult transfusion-
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dependent β-thalassemia patients. We
aimed to achieve a yield of a minimum of
8×106 CD34+cells/kg in apheresis collec-
tion and to assess the effects of plerixafor
addition on the quantity and the quality of
HSPCs that were mobilized. In particular
we were interested in an intraindividual
comparison of counts, subtypes and clono-
genic potency of peripheral blood (PB)
CD34+ cells before and after plerixafor
addition. Moreover, in one patient we com-
pared gene expression analysis of purified
CD34+ cells mobilized with G-
CSF(CD34/G) and with G-CSF+Plerixafor
combination (CD34/G+pl).
Materials and Methods
Study approval
The study was approved by the local
Institutional Ethics Committee and conduct-
ed in the Division of Rare Diseases of Blood
and Hematopoietic Organs-Campus of
Hematology F. and P. Cutino at the Villa
Sofia-Cervello, hospital in Palermo.
Informed consent for privacy and research
use was obtained from all eligible patients in
accordance with the Declaration of Helsinki.
Patient characteristics and
hematopoietic genetically modified
stem and progenitor cells mobilization
Four patients with β-thalassemia major
who were similar in age and weight were
enrolled in the study based on the criteria
listed in Table 1. Patient characteristics are
listed in Table 2. The patients received sub-
cutaneous injections of 10 μg/kg of G-CSF
(Filgrastim, Amgen, Thousand Oaks, CA,
USA) in the morning from day 1 to day 4
and 240 μg/kg of plerixafor (Mozobil,
Sanofi-Genzyme, Cambridge, MA, USA)
on day 4 at 12 hours after treatment with G-
CSF. Leukapheresis was performed 10-12 h
later, on day 5. If fewer than 8×106 CD34+
cells/kg, were collected during the first
apheresis, an additional dose of plerixafor
was administered on the evening of day 5,
and a second apheresis procedure was per-
formed 12 hours later (on day 6). The leuka-
pheresis product was harvested using a cell
separator (COM.TEC® multi-procedural
apheresis platform, Fresenius KABI, Bad
Homburg, Hessen, Germany) according to
institutional standards. The volume of blood
that was processed per leukapheresis was
approximately three times the total blood
volume. The entire process of mobilization
and apheresis was performed in outpatient
clinic. A minimum of 6×106 cells were
immune-enriched and cryopreserved for
future β-globin/lentiviral vector transduc-
tion and a volume of leukapheresis contain-
ing 2×106/kg CD34+ cells was stored as
back-up in case of graft failure, according to
JACIE guidelines, at the Bone Marrow
Transplantation Unit of our hospital. 
Efficacy outcomes and safety
Efficacy outcomes included the number
of patients who reached the target dose, the
number of apheresis that was required, and
the fold increase in circulating CD34+
cells/µl after plerixafor administration.
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Table 1. Eligibility criteria.
Inclusion criteria                                                                                  Exclusion criteria
1.    Diagnosis of ß-Thalassemia Major.                                                                         1.    Hepatitis B and C, HIV 1 and HIV 2, HTLV 1, HTLV2 or other active infections.
2.    Age > 18 years old                                                                                                       2.    Mellitus diabetes.
3.    Lack of an HLA-matched sibling to undergo an allo-trasplantation                3.    History of thrombosis or known thrombophilia (Factor V Leiden, 
                                                                                                                                                       positive anti-phospholipidic-anticardiolipin antibodies).
4.    Without hydroxyurea and erythropoietin administration for at least             4.    Pregnancy or breast-feeding.
       three months before the study.                                                                               
5.    Performance of Karnofsky status > 70.                                                                 5. Severe pulmonary hypertension.
6.    Optimal hepatic function with ALT- <3N, serum total bilirubin <2.0              6. Neoplastic syndrome familiarity.
       (unless secondary to haemolysis), no evidence of cirrhosis 
       in the according to abdomen US and fibroscan.                                                  
7.    FEVS > 50%.                                                                                                                  7. Splenectomized patients with a platelet count > 900.000/mmc.
8.    Renal function: creatinine <1.5 mg/dl, when serum creatinine is outside   
       of the normal range, creatinine clearance (CrCl)>60 ml/min/1.73 m2.          
9.    Splenectomized or non-palpable spleen.                                                              
Table 2. Patient characteristics and side effects during mobilization.
                     Age (yrs)       Gender     Weight (kg)     Genotype (mutation) Chelation  Ferritin (ng/ml)     Spleen             Side effects
Pt 1                             22                         F                         47                                     β0/+                          DFP                       1938                Not palpable                Bone pain
                                                                                                                             Cod39/IVS1-110                                                                                                               Warm feeling
                                                                                                                                                                                                                                                                      Pulse-pounding
Pt 2                             22                        M                        50                                     β+/+                          DFX                      1143.9              Splenectomy                Bone pain
                                                                                                                          IVS 1-110/IVS1-110                                                                                                            Warm feeling
                                                                                                                                                                                                                                                                      Pulse-pounding
                                                                                                                                                                                                                                                                        Leukocytosis
Pt 3                             21                         F                         56                                      +/+                           DFX                       603.4               Not palpable                Bone pain
                                                                                                                               IVS1-6/IVS2-1                                                                                                                      Fatigue
                                                                                                                                                                                                                                                                              Anemia
                                                                                                                                                                                                                                                                   Thrombocytopenia
Pt 4                             23                         F                         51                                      +/+                           DFX                       485.4               Not palpable                Bone pain
                                                                                                                           IVS1-110/IVS2-745                                                                                                       Thrombocytopenia
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Safety was evaluated as the incidence of
adverse events in daily clinical and hemato-
logical follow-ups that were performed dur-
ing and after mobilization, until the com-
plete normalization of blood cell counts was
achieved. In non-splenectomized patients,
the degree of enlargement of the spleen was
evaluated daily using ultrasonography. If
the spleen volume increased by more than
80% from baseline, G-CSF was discontin-
ued, and the patient was withdrawn from
the study. Hyperleukocytosis (WBC
≥50×106/µl) led to a reduction in the G-CSF
dosage or the discontinuation of treatment
in cases of excessive leukocytosis (WBC
≥100×106/µl).
CD34+ cell counts and immune-phe-
notyping
Absolute numbers of PB-CD34+ cells
were measured daily using a flow cytometer
(FC-500 Beckman-Coulter, Cassina de
Pecchi, Milano, Italy) according to the
ISHAGE protocol using a single-platform
method (Stem-Kit, Beckman-Coulter).
CD34+ cell subtyping was performed
after 4 doses of G-CSF (on the morning of
day 4) and at 10-12 hours after plerixafor
administration (on the morning of day 5).
Subtyping was done using a four-colour
method with antibody combinations in a
Beckman Coulter cytometer according to
the manufacturer’s recommendations. Cells
were stained using the following monoclon-
al antibodies or corresponding isotype con-
trols: FITC-conjugated CD45, ECD-conju-
gated CD34, PC5-conjugated CD38
(Beckman Coulter) and PE-conjugated
CD133 (Miltenyi Biotec, Bergisch
Gladbach, Germany). Data were analysed
using the software (Cxp Cytometer analysis
software and Kaluza; Beckman Coulter).
Colony forming unit assay 
Blood samples, containing 3×103
CD34+ cells, collected after G-CSF or G-
CSF+plerixafor mobilization, were cen-
trifuged, and the cellular portion lysed to
eliminate mature erythrocytes. The remain-
ing cells were plated in triplicate in com-
plete methylcellulose medium (MethoCult
H4434 Enriched - StemCell Technology,
Vancouver, British Columbia, Canada) and
incubated at 37°C in 5% CO2 for 14 days.
Identification and counts of colony forming
unit-granulocyte/macrophage (CFU-GM)
and burst-forming unit-erythroid (BFU-E)
were assessed using an inverted micro-
scope. 
The erythroid colonies consisting of
maximum 8 clusters were classified as
small BFU-E, and those that consisted of 9
or more clusters were classified as large
BFU-E.
Microarray hybridization and
analysis
Whole gene expression profiling was
performed on immuno-selected CD34+
cells (purity higher than 90%) using a
CliniMacs CD34Kit (CliniMacs, Miltenyi
Biotec, Bergisch Gladbach, Germany).
CD34+ cells were derived from the leuka-
pheresis of patient 1 that was mobilized
twice, once with G-CSF+plerixafor
(CD34/G+pl) and once, one year later, with
G-CSF alone (CD34/G).
In particular, CD34/G cells were
enriched from the combined leukapheresis
products that were collected, at MSKCC,
NY, USA, for gene therapy purposes on
days 5 and 6 of mobilization using G-CSF
(10 μg/kg/day).6
Total RNA was isolated using TRIZOL
according to the manufacturer’s instructions
(Invitrogen, Carlsbad, CA), and dissolved
to a final concentration of 0.2-0.5 μg/μl.
The quality of the RNA was tested using
capillary electrophoresis in an Agilent 2100
Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA), and the samples exhibited
common high quality RNA integrity num-
bers (RINs) ranging from 8 to 9.
Fluorescently labelled cRNA targets
were generated from 150 ng of total RNA in
each reaction using a Low RNA Input
Linear Amplification Kit and Cyanine 3- or
Cyanine 5-labelled CTP according to the
manufacturer’s instructions (Agilent
Technologies). Labelled cRNAs were puri-
fied using an RNeasy Mini Kit (Qiagen)
and applied to a 4×44 K Whole Human
Genome Oligo Microarray Kit (G4112F,
Agilent Technologies).
For each hybridization, 825 ng of cya-
nine-labelled cRNA from each sample was
mixed with an equal amount of reverse-
colour cyanine-labelled cRNA from
Universal Human Reference RNA
(Stratagene, La Jolla, CA), which was used
as a common reference. Hybridization and
washing were performed using an in situ
hybridization kit according to the manufac-
turer’s instructions (Agilent Technologies).
The arrays were scanned using a dual-laser
DNA microarray scanner (Sure Scan,
Agilent Technologies). The data were then
extracted from the images using Feature
Extraction software (Agilent Technologies,
ver. 9.5.3). All hybridization experiments
were performed in duplicate using dye-
swap.
GeneSpring software (GX software ver.
11, Agilent Technologies), and lists of
selected genes were generated using differ-
ent statistical and visualization methods.
Intensity-dependent normalization (known
as Lowess normalization) was used to cor-
rect for the artefacts that were caused by
non-linear rates of dye incorporation and
inconsistencies in the relative fluorescence
intensities between some red and green
dyes.
The data from the CD34/G+pl and
CD34/G RNA samples were then normal-
ized to the Universal Human Reference
RNA (Stratagene, La Jolla, CA), and an ini-
tial gene list was created using confidence
filtering at P<0.01 (t-test P-values were
used as the measure of confidence, and the
Benjamini-Hochberg false discovery rate
was used for multiple testing correction) to
eliminate genes with unreliable measure-
ments. Consecutive lists of differentially
expressed genes were generated assuming a
2-fold expression rate and using data from
all independent experiments.
Gene ontology analysis was first per-
formed using DAVID Bioinformatics
Resource online software (ver. 6.7, NIAID,
NIH: http://david.abcc.ncifcrf.gov/), and
pathway analysis was subsequently per-
formed using the same software.
The data reported here have been
deposited in the National Centre for
Biotechnology Information’s Gene
Expression Omnibus (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE70219)
Statistical analysis
The data are provided as the median,
range or maximum values. Mean, standard
deviation and p-value were performed with
the STATA 12.0 software (StataCorp, USA)
applying the Student t-test.
Results
Patients and safety
According to the Common Terminology
Criteria for Adverse Events, version 4.0, the
treatment was well tolerated with minimal
side effects (Table 2). The splenectomized
patient (Pt 2) developed hyperleukocytosis
(WBC 60.2×106/µl) and required the G-
CSF dosage dose to be halved from day 2 of
mobilization (Table 3). 
An average Hb reduction of 0.9 g/dl and
an average reduction in platelet numbers
were observed at the end of the mobiliza-
tion period compared with baseline
(354.5±187.8 vs 175±97.5). After the sec-
ond apheresis, patient 3 developed interme-
diate grade thrombocytopenia (platelet
count of 68.0/µl) that recovered completely
within one week and a reduction in hemo-
globin levels to 8.7 g/dl, which required a
blood transfusion. 
Other mild side effects lasted for 1-2
days after apheresis and resolved sponta-
neously. The patient’s hematological
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parameters during mobilization are shown
in Table 3.
G-CSF+plerixafor results in efficient
CD34+ cell mobilization
8×106 CD34+ cells/kg was defined as
target cell dose for gene therapy. Three out
of four patients achieved the target cell dose
in a single apheresis collection (8.15×10/6
cells/kg, median value), including the
patient 2, despite the fact that G-CSF dose
was reduced in this patient starting from
day 2 to avoid hyperleukocytosis (Table 3).
In patient 3, the number of cells collect-
ed in the first apheresis was slightly below
the established target and a second aphere-
sis collection was performed on day 6, at 12
hours after an additional dose of plerixafor
was administered. The total yield from the
combined apheresis in this patient was 13.5
CD34+ cells/kg (Pt 3, Table 3). The kinetics
of HSPC mobilization were analysed by
counting the PB-CD34+ cell daily during
treatment (Table 3). The addition of plerix-
afor mobilized a substantial portion of
CD34+ cells in all of the patients, resulting
in a 12-fold mean peak increase (range, 4.8-
to 23-fold). 
Addition of plerixafor increases the
mobilization of CD34+ cell subsets
with a more primitive phenotype
and higher clonogenic capacity
To investigate whether plerixafor expo-
sure causes the release of a subset of HSPCs
distinct from GCSF-primed progenitor
cells, we studied the co-expression of the
surface antigens CD133 and CD38 in PB-
CD34+ cells before and after plerixafor was
administered. 
The frequency of primitive CD34+ sub-
types (CD34+/CD38- and CD34+/CD133+)
consistently increased in all patients after
plerixafor was added. CD34+/CD38- cells
were increased by 2.4-fold, despite the high
inter-individual variability that was
observed at baseline, and CD34+/CD133+
cells were increased by 1.3-fold. A signifi-
cant increase was also observed in the fre-
quency of the most primitive CD34+ sub-
type, CD34+/CD133+/CD38- cells, after
plerixafor addition. The same analysis per-
formed in PB sample obtained from patient
3 at 11 hours after the second administration
of plerixafor, showed no change in the pro-
portion of CD34+ subtypes compared to
that of the day before (data not shown).
These data suggest that the difference in
subset composition that was observed
between days 4 and 5 can be attributed to
plerixafor stimulation instead of a longer
period of mobilization. In support of this
hypothesis, we also did not detect substan-
tial changes in the proportion of PB-CD34+
cell subtypes in the three healthy donors on
days 4 and 5 during mobilization with G-
CSF (10 μg/kg/day) used as single agent
(data not shown). These data are in line with
those reported by others regarding the fre-
quency of CD34+/CD38- cells in PB of
donors on days 4, 5 and 6 of G-CSF mobi-
lization.18
Clonogenic capacity of PB CD34+ cells
was investigated in short-term colony form-
ing (CFC) assay based on the numbers and
types of colonies that developed, before and
after plerixafor.
The absolute number of CFU-GM and
BFU-E that developed from PB-CD34+
cells plated at day 5 was unanimously high-
er than that developed from the same num-
ber of cells plated, before plerixafor addi-
tion. In addition, the proliferative capacity
of the progenitors also increased after pler-
ixafor was added, as observed comparing
the sizes of the BFU-E colonies that devel-
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Table 3. Blood CD34+ cell counts and hematological parameters during G-CSF+plerixafor mobilization.
                                        Day                        +1                   +2                    +3                         +4                  +5*              +6*               +7
Pt 1                                      WBC 103/uL                         6.6                        25.0                        32.1                              30.0                       60.3                   19.4                       
                                              ANC 103/uL                          3.9                        21.4                        27.1                              24.3                       40.2                   14.1                       
                                               HGB g/dL                          11.5                       10.9                        10.7                              10.6                       10.6                   10.0                       
                                              PLT 103/uL                          294                        260                         262                               279                        318                    211                        
                                              CD34+/uL                            4                            8                            10                                  48                         361                     80                         
                                              CD34+/Kg                                                                                                                                                          29×106                                               
Pt 2°                                    WBC 103/uL                        12.8                       60.2                        56.6                              55.8                       92.2                   21.5                       
                                             ANC 103/ /uL                         5.9                         NA                          NA                                NA                        61.6                   13.7                       
                                               HGB g/dL                          10.9                       10.7                         9.7                               10.8                       10.1                   10.2                       
                                              PLT 103/uL                          633                        587                         503                               588                        538                    292                        
                                              CD34+/uL                            6                            6                             6                                   19                          92                      NA                        
                                              CD34+/Kg                                                                                                                                                         8.3×106                                               
Pt 3                                      WBC 103/uL                         4.2                        24.3                        27.5                              30.0                       68.1                   65.0                    38.0
                                              ANC 103/uL                          2.1                        19.8                        22.8                              25.7                       42.3                    NA                     NA
                                               HGB g/dL                          11.2                        9.2                          9.0                                 9.8                         9.5                    10.0                     8.7
                                              PLT 103/uL                          225                        220                         213                               250                        239                    120                      68
                                              CD34+/uL                            1                            1                             1                                    5                          115                     76                      NA
                                              CD34+/Kg                                                                                                                                                           7×106              6.5×106                   
Pt 4                                      WBC 103/uL                         6.2                        20.6                          21                                25.1                         53                      NA                        
                                              ANC 103/uL                          3.3                        18.4                        18.3                              21.7                       42.9                    NA                        
                                               HGB g/dL                          10.7                       10.7                        11.5                              10.6                       10.7                   10.4                       
                                              PLT 103/uL                          266                        263                         238                               211                        217                    129                        
                                              CD34+/uL                            1                            1                             1                                    8                          102                     NA                        
                                              CD34+/Kg                                                                                                                                                           8×106                                                
Values obtained after administration of plerixafor to GCSF regimen are indicated in italics. WBC, white blood cell; ANC, absolute neutrophil count; HGB, hemoglobin; PLT, platelet. *Days of treatment when the phe-
notype and clonogenic ability were analyzed; °in this patient, the G-CSF dosage was halved beginning on day 2 of mobilization.
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oped from PB-CD34+ cells at these two
time points. On day 5 of mobilization, we
observed a clear increase in the portion of
intermediate/large BFU-E colonies that
consisted of more than 9 clusters over the
total number of BFU-E colonies. 
G-CSF+Plerixafor combination
mobilizes of CD34+ cells with gene
expression pattern distinct from that
of G-CSF-primed cells
We performed a microarray analysis to
analyse global gene expression in CD34+
cells that were purified from the leuka-
pheresis of patient 1 by two independent
mobilization regimens: one with G-
CSF+plerixafor (CD34/G+pl) and one, with
G-CSF used as a single agent (CD34/G). 
The CD34/G and CD34/G+pl samples
were compared after normalization using
Universal Human Reference RNA
(Stratagene) as a common reference. 
A subset of differentially expressed
genes was selected from all of the microar-
ray data after they were first filtered accord-
ing to confidence at P<0.01 and then by
expression level (≥2-fold). Using these
selection criteria, we found that 873 genes
were commonly up-regulated and that 1691
genes were down-regulated in the
CD34/G+pl cells than in the CD34/G cells.
The genes were classified according to
their function using the Gene Ontology
Classification System (Figure 1A and
Supplementary Table 1). As shown in
Figure 1B a substantial number of genes
associated with homing and engraftment
processes (e.g., CXCR4, CD82, DPP4 and
ROBO4) and genes known to be linked to
stress resistance (e.g., CXCL4, SOD2, IL8
and PPBP) were up-regulated. Several
genes, encoding chemokines that have been
shown to be involved in cell mobility (e.g.,
CXCL2, CXC3 and CXCR2) were also up-
regulated, and genes involved in transcrip-
tional regulation (e.g., GATA-2, BTG2,
DUSP2, MS4A3 and TNF) were either up-
or down-regulated. The array analysis also
indicated in both CD34/G+pl and CD34/G
cells the substantial over-expression (more
than 16-fold compared to the Universal
Reference RNA) of several genes (RGS18,
MPO, TNFSF4, EGR1) that are involved in
mobilization, homeostasis, homing and
engraftment (data not shown).
Discussion
The outcome of gene therapy for β-tha-
lassemia, in addition to requiring sufficient
genetic modification of CD34+ cells, and
efficient myeloablative conditioning, large-
ly depends on the quantity and the quality of
the autologous hematopoietic stem cell col-
lected. Indeed, to reduce morbidity result-
ing from ineffective erythropoiesis and to
achieve transfusion independence, it is nec-
essary to infuse an adequate number of
HSPCs that are capable of generating long-
term gene-corrected erythroid precursors.
In this study, G-CSF+plerixafor mobi-
lization was shown to be safe and effica-
cious for collecting high numbers of
HSPCs. The target cell dose was achieved
in all patients, and in three of them, it was
achieved in a single apheresis collection.
This result was similar to that previously
reported by Yannaki and co-workers, in
other 4 patients mobilized using the same
combination;17 conversely, in other studies
in which G-CSF was used as a single agent,
similar cell yields were achieved after two
apheresis collections in the majority of the
patients.14,6
It has been shown that G-CSF and pler-
ixafor promote HSPCs trafficking via dif-
ferent mechanisms, that may explain differ-
ent HSPC subsets.19 
Papers describing differences in G-CSF
and G-CSF+plerixafor grafts in healthy
donors and onco-hematological patients
have concluded that CD34/G+pl cells show
more immature phenotypes than CD34/G
cells.15,20-24
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Figure 1. Bar graph representations of the differential expression profiles of genes that
were analysed in the microarray analysis. A) Bar graph of biological process overrepre-
sented in CD34/G+pl cells compared to CD34/G cells. B) Log changes are shown to rep-
resent the difference in the expression level of genes differentially expressed between
CD34/G+pl cells and CD34/G cells. -Log2-fold changes (FC) were calculated after nor-
malization to Universal Reference RNA (P<0.01, FC cut-off ±2). Values greater than or
equal to 1 represent gene up-regulation, and values less than 1 indicate gene down-regu-
lation.
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However, the hematopoietic cell reper-
toire in thalassemia patients may differ from
that of other subjects because they endure
chronic anaemia, prolonged transfusion
regimens, and iron overload may alter the
balance that regulates the retention/release
of these cells. We were interested in charac-
terizing intra-individual variations in
CD34+ cells that were mobilized using G-
CSF or G-CSF+plerixafor.
We found that the addition of plerixafor
uniformly resulted in a substantial increase
in the proportion of primitive CD34+ sub-
types that have previously been shown to
possess extensive proliferation and repopu-
lation capacities.25,26 Moreover, CD34/G+pl
cells displayed a higher capacity for clono-
genicity and proliferation than CD34/G
cells from the same patients. A trend
towards higher frequencies of primitive
cells has been previously observed in G-
CSF+plerixafor grafts (compared to single-
agent-mobilized grafts) obtained from tha-
lassemia patients and from mouse model of
thalassemia.14,17,27
Our results corroborate and extend on
this finding at an intra-patient level that
allowed us to abolish variability in cellular
composition between individuals. 
Expression profiling of CD34/G and
CD34/G+pl cells, derived from patients
with hematologic malignancies,28 and pri-
mates29 mobilized with both modalities,
revealed that CD34/G+pl cells expressed
significantly higher levels of genes that pro-
mote superior engraftment after myeloabla-
tion. We found that also in thalassemia
patients, gene expression profiles depended
on the mobilization protocol. This result
may explain published functional data that
have shown that G-CSF+Plerixafor grafts
obtained from thalassemia patients are more
competitive than G-CSF grafts at engrafting
murine recipients.30
In particular, according to the mecha-
nism of plerixafor mobilization, the expres-
sion level of CXCR4 was 5-fold higher in
CD34/G+pl cells than in CD34/G cells.
This result was analogous to that reported
by Fruehauf and co-workers in patients with
multiple myeloma and non-Hodgkin lym-
phoma.28
CXCR4 is expressed on the surface of
HSPCs, especially more primitive
CD34+ cells with long-term repopulating
potential, and it plays a central role in
regulating the adhesion of HSPCs to their
native niche in BM.31 Conversely, genes
involved in the cleavage of VCAM-1 and
SDF-1 (CXCL12) antigens, such as elas-
tase (ELANE) and cathepsin G (CTSG),
were overexpressed in both CD34/G+pl
and CD34/G cells. These data are in line
with a mechanism involving G-CSF
mobilization.32
The chemokines CXCL2, CXC3 and
CXCR2 , involved in a rapid HSPCs mobi-
lization, were also up-regulated in
CD34/G+pl cells.33 Among the genes that
were found to be differentially expressed in
the two samples, there was a group of anti-
gen surface genes that regulate adhesion to
the microenvironment. In particular, CD82
and Robo4 were overexpressed and CD26
was down-regulated in CD34/G+pl cells. It
has been reported both CD82 and Robo 4
play a key role in anchoring HSPC to BM
niches and in long-term reconstitution,34,35
while inhibiting CD26 may increase the
success of HSPC transplantation.36 
Several transcription regulators have
also been shown to be up-regulated in
CD34/G+pl cells. Among these, GATA-2,
BTG2/TIS21 and DUSP2 are of particular
relevance. GATA-2 acts as a regulator of
hematopoiesis, during which it inhibits dif-
ferentiation by preventing the activation of
lineage-specific genes.37 Furthermore,
BTG2/TIS21 and DUSP2 are negative cell-
cycle regulators of cell proliferation.38 
In particular DUSP2-mediated suppres-
sion of ERK activity is required to maintain
a pluripotent state in murine stem cells.39
A group of genes, superoxide dismutase
2 (SOD2), CXC-type chemokine PF4
(CXCL4), IL-8 and NAP-2 (PPBP) that
improve cell survival and reduce cell sensi-
tivity to cytotoxic agents limiting the harm-
ful effects of cellular stress caused by the
mobilization process, was also significantly
expressed in CD34/G+pl cells.40,41
Interestingly, the expression levels of
MS4A3 and tumour necrosis factor (TNF),
which influence the fate of HSPCs by
directing them towards differentiation
instead of self-renewal,42-44 were down-reg-
ulated in CD34/G+pl cells. Several other
genes (RSGS18, MPO, TNFSF4 and
EGR1) involved in mobilization, homeosta-
sis, homing, engraftment, cell survival and
self-renewal were also substantially overex-
pressed in both samples. 
Conclusions
Overall, the mobilization study reported
here, in thalassemia patients, highlighted
how the addiction of plerixafor to G-CSF-
based mobilization not only enhanced cell
yields, but also promoted the egress from
BM of CD34+ cells with phenotypic and
functional characteristics and gene expres-
sion profiles that suggest high capacity of
engraftment after transplantation.
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ID Biological Process Description Fold 
enrichment
Percentage 
of genes p‐value  p‐value FDR
GO:0002819 regulation of adaptive immune response 12.50 0.28 2.60E‐07 2.96E‐03
GO:0045646 regulation of erythrocyte differentiation 12.50 0.24 3.26E‐06 3.71E‐02
GO:0045577 regulation of B cell differentiation 10.72 0.28 1.70E‐06 1.93E‐02
GO:0060216 definitive hemopoiesis 7.36 0.47 1.21E‐07 1.38E‐03
GO:0048535 lymph node development 6.26 0.38 1.19E‐05 1.35E‐01
GO:0030225 macrophage differentiation 5.56 0.38 3.48E‐05 3.97E‐01
GO:0050853 B cell receptor signaling pathway 5.15 0.99 9.10E‐11 1.04E‐06
GO:0071345  cellular response to cytokine stimulus 5.12 0.42 2.50E‐05 2.85E‐01
GO:0042102 positive regulation of T cell proliferation 4.74 1.04 2.20E‐10 2.51E‐06
GO:0006952  defense response 4.24 0.94 1.40E‐08 1.59E‐04
GO:0031295 T cell costimulation 4.17 1.23 1.49E‐10 1.70E‐06
GO:0050727 regulation of inflammatory response 3.82 0.85 4.47E‐07 5.10E‐03
GO:0030097 hemopoiesis 3.47 0.71 1.44E‐05 1.64E‐01
GO:0002250 adaptive immune response 3.35 1.93 2.97E‐12 3.38E‐08
GO:0002244 hemopoietic progenitor cell differentiation 3.18 0.71 4.54E‐05 5.17E‐01
GO:0006954 inflammatory response 3.11 4.34 3.18E‐23 3.62E‐19
GO:0006955 immune response 3.02 4.34 2.91E‐22 3.31E‐18
GO:0042127 regulation of cell proliferation 2.90 1.84 1.03E‐09 1.17E‐05
GO:0050900  leukocyte migration 2.87 1.32 2.88E‐07 3.28E‐03
GO:0050776 regulation of immune response 2.81 1.89 1.74E‐09 1.99E‐05
GO:0045087 innate immune response 2.70 4.11 8.39E‐18 9.56E‐14
GO:0019221 cytokine‐mediated signaling pathway 2.44 1.13 3.68E‐05 4.19E‐01
GO:0035556 intracellular signal transduction 2.33 3.35 1.57E‐11 1.79E‐07
GO:0016477  cell migration 2.23 1.42 2.56E‐05 2.92E‐01
GO:0006915 apoptotic process 2.15 4.29 2.84E‐12 3.23E‐08
GO:0001525  angiogenesis 2.04 1.65 4.39E‐05 5.00E‐01
GO:0007166 cell surface receptor signaling pathway 2.01 2.03 8.30E‐06 9.45E‐02
GO:0007165  signal transduction 1.91 7.74 3.45E‐16 3.93E‐12
GO:0006355 transcription, DNA‐dependent 1.90 12.84 2.86E‐26 3.26E‐22
GO:0006366 transcription from RNA polymerase II promoter 1.61 3.11 8.71E‐05 9.93E‐01
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